Company

BioInvent International AB

Headquarters: Lund, Sweden

Employees: 84

CEO: Dr. Martin Welschof Ph.D.

FSX: BIX0 +3.06%

Market Cap

€199.5 Million

EUR as of July 1, 2024

US$214.3 Million

Market Cap History

BioInvent International AB market capitalization over time

Evolution of BioInvent International AB market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of BioInvent International AB

Detailed Description

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

BioInvent International AB has the following listings and related stock indices.


Stock: FSX: BIX0 wb_incandescent

Details

Headquarters:

The Gamma Building

Ideongatan 1

Lund, 223 70

Sweden

Phone: 46 4 62 86 85 50